Another vaccine under investigation is Belagenpumatucel-L, a vaccine composed of tumor cells transfected with a TGF- β2 antisense vector; this has been hypothesized to work by increasing tumor antigen recognition and inhibiting the immunosuppressive function of TGF-β2. Here, TGFB2 is linked to neoplasm.